nodes	percent_of_prediction	percent_of_DWPC	metapath
Prasugrel—ALB—Vandetanib—thyroid cancer	0.233	0.301	CbGbCtD
Prasugrel—CYP2B6—Sorafenib—thyroid cancer	0.143	0.185	CbGbCtD
Prasugrel—CYP2C19—Sorafenib—thyroid cancer	0.091	0.118	CbGbCtD
Prasugrel—CYP2B6—Doxorubicin—thyroid cancer	0.0869	0.112	CbGbCtD
Prasugrel—CYP2C9—Sorafenib—thyroid cancer	0.0756	0.0978	CbGbCtD
Prasugrel—CYP3A4—Vandetanib—thyroid cancer	0.0729	0.0944	CbGbCtD
Prasugrel—CYP3A4—Sorafenib—thyroid cancer	0.044	0.0569	CbGbCtD
Prasugrel—CYP3A4—Doxorubicin—thyroid cancer	0.0267	0.0345	CbGbCtD
Prasugrel—Haemoptysis—Vandetanib—thyroid cancer	0.0081	0.0366	CcSEcCtD
Prasugrel—Haematoma—Sorafenib—thyroid cancer	0.00644	0.029	CcSEcCtD
Prasugrel—Neoplasm—Vandetanib—thyroid cancer	0.00542	0.0245	CcSEcCtD
Prasugrel—Neoplasm malignant—Sorafenib—thyroid cancer	0.00474	0.0214	CcSEcCtD
Prasugrel—Atrial fibrillation—Vandetanib—thyroid cancer	0.00459	0.0207	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Vandetanib—thyroid cancer	0.00435	0.0196	CcSEcCtD
Prasugrel—Haematochezia—Epirubicin—thyroid cancer	0.00371	0.0168	CcSEcCtD
Prasugrel—Neoplasm—Sorafenib—thyroid cancer	0.00366	0.0165	CcSEcCtD
Prasugrel—Pericardial effusion—Epirubicin—thyroid cancer	0.00364	0.0164	CcSEcCtD
Prasugrel—Haematochezia—Doxorubicin—thyroid cancer	0.00343	0.0155	CcSEcCtD
Prasugrel—Pericardial effusion—Doxorubicin—thyroid cancer	0.00337	0.0152	CcSEcCtD
Prasugrel—Haematuria—Vandetanib—thyroid cancer	0.0032	0.0144	CcSEcCtD
Prasugrel—Epistaxis—Vandetanib—thyroid cancer	0.00316	0.0143	CcSEcCtD
Prasugrel—Bradycardia—Vandetanib—thyroid cancer	0.00307	0.0138	CcSEcCtD
Prasugrel—Haemoglobin—Vandetanib—thyroid cancer	0.00303	0.0137	CcSEcCtD
Prasugrel—Haemorrhage—Vandetanib—thyroid cancer	0.00301	0.0136	CcSEcCtD
Prasugrel—Urinary tract disorder—Vandetanib—thyroid cancer	0.00297	0.0134	CcSEcCtD
Prasugrel—Urethral disorder—Vandetanib—thyroid cancer	0.00295	0.0133	CcSEcCtD
Prasugrel—Pain in extremity—Sorafenib—thyroid cancer	0.00294	0.0133	CcSEcCtD
Prasugrel—Eye disorder—Vandetanib—thyroid cancer	0.00281	0.0127	CcSEcCtD
Prasugrel—Angiopathy—Vandetanib—thyroid cancer	0.00273	0.0123	CcSEcCtD
Prasugrel—Mediastinal disorder—Vandetanib—thyroid cancer	0.00271	0.0122	CcSEcCtD
Prasugrel—Gingival bleeding—Epirubicin—thyroid cancer	0.00263	0.0119	CcSEcCtD
Prasugrel—Gingival bleeding—Doxorubicin—thyroid cancer	0.00244	0.011	CcSEcCtD
Prasugrel—Cough—Vandetanib—thyroid cancer	0.00229	0.0103	CcSEcCtD
Prasugrel—Hypertension—Vandetanib—thyroid cancer	0.00226	0.0102	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00222	0.01	CcSEcCtD
Prasugrel—Epistaxis—Sorafenib—thyroid cancer	0.00213	0.00963	CcSEcCtD
Prasugrel—Thrombocytopenia—Vandetanib—thyroid cancer	0.00209	0.00945	CcSEcCtD
Prasugrel—Skin disorder—Vandetanib—thyroid cancer	0.00208	0.00938	CcSEcCtD
Prasugrel—Hyperlipidaemia—Epirubicin—thyroid cancer	0.00207	0.00936	CcSEcCtD
Prasugrel—Haemoglobin—Sorafenib—thyroid cancer	0.00204	0.00921	CcSEcCtD
Prasugrel—Haemorrhage—Sorafenib—thyroid cancer	0.00203	0.00917	CcSEcCtD
Prasugrel—Haemoptysis—Epirubicin—thyroid cancer	0.00202	0.00912	CcSEcCtD
Prasugrel—Urinary tract disorder—Sorafenib—thyroid cancer	0.00201	0.00905	CcSEcCtD
Prasugrel—Urethral disorder—Sorafenib—thyroid cancer	0.00199	0.00899	CcSEcCtD
Prasugrel—Hyperlipidaemia—Doxorubicin—thyroid cancer	0.00192	0.00866	CcSEcCtD
Prasugrel—Dyspnoea—Vandetanib—thyroid cancer	0.00191	0.00861	CcSEcCtD
Prasugrel—Haemoptysis—Doxorubicin—thyroid cancer	0.00187	0.00843	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00185	0.00834	CcSEcCtD
Prasugrel—Fatigue—Vandetanib—thyroid cancer	0.00184	0.00832	CcSEcCtD
Prasugrel—Angiopathy—Sorafenib—thyroid cancer	0.00184	0.00832	CcSEcCtD
Prasugrel—Immune system disorder—Sorafenib—thyroid cancer	0.00183	0.00828	CcSEcCtD
Prasugrel—Mediastinal disorder—Sorafenib—thyroid cancer	0.00183	0.00826	CcSEcCtD
Prasugrel—Neoplasm malignant—Epirubicin—thyroid cancer	0.00175	0.0079	CcSEcCtD
Prasugrel—Body temperature increased—Vandetanib—thyroid cancer	0.00169	0.00763	CcSEcCtD
Prasugrel—Rectal haemorrhage—Epirubicin—thyroid cancer	0.00165	0.00747	CcSEcCtD
Prasugrel—Anaemia—Sorafenib—thyroid cancer	0.00163	0.00738	CcSEcCtD
Prasugrel—Neoplasm malignant—Doxorubicin—thyroid cancer	0.00162	0.00731	CcSEcCtD
Prasugrel—Angioedema—Sorafenib—thyroid cancer	0.00162	0.00729	CcSEcCtD
Prasugrel—Leukopenia—Sorafenib—thyroid cancer	0.00158	0.00714	CcSEcCtD
Prasugrel—Cough—Sorafenib—thyroid cancer	0.00154	0.00696	CcSEcCtD
Prasugrel—Asthenia—Vandetanib—thyroid cancer	0.00153	0.00693	CcSEcCtD
Prasugrel—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.00153	0.00691	CcSEcCtD
Prasugrel—Hypertension—Sorafenib—thyroid cancer	0.00153	0.00689	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00149	0.00675	CcSEcCtD
Prasugrel—Diarrhoea—Vandetanib—thyroid cancer	0.00146	0.00661	CcSEcCtD
Prasugrel—Anaphylactic shock—Sorafenib—thyroid cancer	0.00144	0.00651	CcSEcCtD
Prasugrel—Dizziness—Vandetanib—thyroid cancer	0.00141	0.00639	CcSEcCtD
Prasugrel—Thrombocytopenia—Sorafenib—thyroid cancer	0.00141	0.00638	CcSEcCtD
Prasugrel—Skin disorder—Sorafenib—thyroid cancer	0.0014	0.00633	CcSEcCtD
Prasugrel—Ecchymosis—Epirubicin—thyroid cancer	0.00135	0.0061	CcSEcCtD
Prasugrel—Neoplasm—Epirubicin—thyroid cancer	0.00135	0.0061	CcSEcCtD
Prasugrel—Rash—Vandetanib—thyroid cancer	0.00135	0.00609	CcSEcCtD
Prasugrel—Dermatitis—Vandetanib—thyroid cancer	0.00135	0.00608	CcSEcCtD
Prasugrel—Headache—Vandetanib—thyroid cancer	0.00134	0.00605	CcSEcCtD
Prasugrel—Dyspnoea—Sorafenib—thyroid cancer	0.00129	0.00581	CcSEcCtD
Prasugrel—Nausea—Vandetanib—thyroid cancer	0.00127	0.00574	CcSEcCtD
Prasugrel—Ecchymosis—Doxorubicin—thyroid cancer	0.00125	0.00564	CcSEcCtD
Prasugrel—Neoplasm—Doxorubicin—thyroid cancer	0.00125	0.00564	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00125	0.00562	CcSEcCtD
Prasugrel—Fatigue—Sorafenib—thyroid cancer	0.00124	0.00562	CcSEcCtD
Prasugrel—Body temperature increased—Sorafenib—thyroid cancer	0.00114	0.00515	CcSEcCtD
Prasugrel—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00111	0.005	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00109	0.0049	CcSEcCtD
Prasugrel—Pain in extremity—Epirubicin—thyroid cancer	0.00109	0.0049	CcSEcCtD
Prasugrel—Hypersensitivity—Sorafenib—thyroid cancer	0.00106	0.0048	CcSEcCtD
Prasugrel—Asthenia—Sorafenib—thyroid cancer	0.00104	0.00467	CcSEcCtD
Prasugrel—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00102	0.00462	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.001	0.00453	CcSEcCtD
Prasugrel—Pain in extremity—Doxorubicin—thyroid cancer	0.001	0.00453	CcSEcCtD
Prasugrel—Diarrhoea—Sorafenib—thyroid cancer	0.000987	0.00446	CcSEcCtD
Prasugrel—Dizziness—Sorafenib—thyroid cancer	0.000954	0.00431	CcSEcCtD
Prasugrel—Rash—Sorafenib—thyroid cancer	0.00091	0.00411	CcSEcCtD
Prasugrel—Dermatitis—Sorafenib—thyroid cancer	0.000909	0.0041	CcSEcCtD
Prasugrel—Headache—Sorafenib—thyroid cancer	0.000904	0.00408	CcSEcCtD
Prasugrel—Nausea—Sorafenib—thyroid cancer	0.000857	0.00387	CcSEcCtD
Prasugrel—Haematuria—Epirubicin—thyroid cancer	0.000797	0.0036	CcSEcCtD
Prasugrel—Epistaxis—Epirubicin—thyroid cancer	0.000789	0.00356	CcSEcCtD
Prasugrel—Bradycardia—Epirubicin—thyroid cancer	0.000764	0.00345	CcSEcCtD
Prasugrel—Haemoglobin—Epirubicin—thyroid cancer	0.000754	0.00341	CcSEcCtD
Prasugrel—Haemorrhage—Epirubicin—thyroid cancer	0.000751	0.00339	CcSEcCtD
Prasugrel—Urinary tract disorder—Epirubicin—thyroid cancer	0.000741	0.00335	CcSEcCtD
Prasugrel—Oedema peripheral—Epirubicin—thyroid cancer	0.000739	0.00334	CcSEcCtD
Prasugrel—Haematuria—Doxorubicin—thyroid cancer	0.000738	0.00333	CcSEcCtD
Prasugrel—Urethral disorder—Epirubicin—thyroid cancer	0.000736	0.00332	CcSEcCtD
Prasugrel—Epistaxis—Doxorubicin—thyroid cancer	0.00073	0.00329	CcSEcCtD
Prasugrel—Bradycardia—Doxorubicin—thyroid cancer	0.000707	0.00319	CcSEcCtD
Prasugrel—Eye disorder—Epirubicin—thyroid cancer	0.000702	0.00317	CcSEcCtD
Prasugrel—Haemoglobin—Doxorubicin—thyroid cancer	0.000698	0.00315	CcSEcCtD
Prasugrel—Haemorrhage—Doxorubicin—thyroid cancer	0.000695	0.00314	CcSEcCtD
Prasugrel—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000686	0.0031	CcSEcCtD
Prasugrel—Oedema peripheral—Doxorubicin—thyroid cancer	0.000684	0.00309	CcSEcCtD
Prasugrel—Angiopathy—Epirubicin—thyroid cancer	0.000681	0.00307	CcSEcCtD
Prasugrel—Urethral disorder—Doxorubicin—thyroid cancer	0.000681	0.00307	CcSEcCtD
Prasugrel—Immune system disorder—Epirubicin—thyroid cancer	0.000678	0.00306	CcSEcCtD
Prasugrel—Mediastinal disorder—Epirubicin—thyroid cancer	0.000677	0.00305	CcSEcCtD
Prasugrel—Eye disorder—Doxorubicin—thyroid cancer	0.000649	0.00293	CcSEcCtD
Prasugrel—Back pain—Epirubicin—thyroid cancer	0.000632	0.00285	CcSEcCtD
Prasugrel—Angiopathy—Doxorubicin—thyroid cancer	0.00063	0.00284	CcSEcCtD
Prasugrel—Immune system disorder—Doxorubicin—thyroid cancer	0.000627	0.00283	CcSEcCtD
Prasugrel—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000626	0.00283	CcSEcCtD
Prasugrel—Anaemia—Epirubicin—thyroid cancer	0.000604	0.00273	CcSEcCtD
Prasugrel—Leukopenia—Epirubicin—thyroid cancer	0.000585	0.00264	CcSEcCtD
Prasugrel—Back pain—Doxorubicin—thyroid cancer	0.000585	0.00264	CcSEcCtD
Prasugrel—Cough—Epirubicin—thyroid cancer	0.00057	0.00257	CcSEcCtD
Prasugrel—CES2—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.000569	0.104	CbGpPWpGaD
Prasugrel—Hypertension—Epirubicin—thyroid cancer	0.000564	0.00255	CcSEcCtD
Prasugrel—Anaemia—Doxorubicin—thyroid cancer	0.000559	0.00252	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000553	0.00249	CcSEcCtD
Prasugrel—Leukopenia—Doxorubicin—thyroid cancer	0.000541	0.00244	CcSEcCtD
Prasugrel—Anaphylactic shock—Epirubicin—thyroid cancer	0.000533	0.00241	CcSEcCtD
Prasugrel—Cough—Doxorubicin—thyroid cancer	0.000528	0.00238	CcSEcCtD
Prasugrel—Thrombocytopenia—Epirubicin—thyroid cancer	0.000522	0.00236	CcSEcCtD
Prasugrel—Hypertension—Doxorubicin—thyroid cancer	0.000522	0.00236	CcSEcCtD
Prasugrel—Skin disorder—Epirubicin—thyroid cancer	0.000518	0.00234	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000511	0.00231	CcSEcCtD
Prasugrel—Hypotension—Epirubicin—thyroid cancer	0.000498	0.00225	CcSEcCtD
Prasugrel—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000493	0.00223	CcSEcCtD
Prasugrel—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000483	0.00218	CcSEcCtD
Prasugrel—Skin disorder—Doxorubicin—thyroid cancer	0.000479	0.00216	CcSEcCtD
Prasugrel—Dyspnoea—Epirubicin—thyroid cancer	0.000475	0.00215	CcSEcCtD
Prasugrel—Hypotension—Doxorubicin—thyroid cancer	0.000461	0.00208	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00046	0.00208	CcSEcCtD
Prasugrel—Fatigue—Epirubicin—thyroid cancer	0.00046	0.00208	CcSEcCtD
Prasugrel—Dyspnoea—Doxorubicin—thyroid cancer	0.00044	0.00199	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000426	0.00192	CcSEcCtD
Prasugrel—Fatigue—Doxorubicin—thyroid cancer	0.000425	0.00192	CcSEcCtD
Prasugrel—Body temperature increased—Epirubicin—thyroid cancer	0.000422	0.0019	CcSEcCtD
Prasugrel—Hypersensitivity—Epirubicin—thyroid cancer	0.000393	0.00177	CcSEcCtD
Prasugrel—Body temperature increased—Doxorubicin—thyroid cancer	0.00039	0.00176	CcSEcCtD
Prasugrel—Asthenia—Epirubicin—thyroid cancer	0.000383	0.00173	CcSEcCtD
Prasugrel—Diarrhoea—Epirubicin—thyroid cancer	0.000365	0.00165	CcSEcCtD
Prasugrel—Hypersensitivity—Doxorubicin—thyroid cancer	0.000364	0.00164	CcSEcCtD
Prasugrel—Asthenia—Doxorubicin—thyroid cancer	0.000354	0.0016	CcSEcCtD
Prasugrel—Dizziness—Epirubicin—thyroid cancer	0.000353	0.00159	CcSEcCtD
Prasugrel—Diarrhoea—Doxorubicin—thyroid cancer	0.000338	0.00152	CcSEcCtD
Prasugrel—Rash—Epirubicin—thyroid cancer	0.000336	0.00152	CcSEcCtD
Prasugrel—Dermatitis—Epirubicin—thyroid cancer	0.000336	0.00152	CcSEcCtD
Prasugrel—Headache—Epirubicin—thyroid cancer	0.000334	0.00151	CcSEcCtD
Prasugrel—Dizziness—Doxorubicin—thyroid cancer	0.000326	0.00147	CcSEcCtD
Prasugrel—Nausea—Epirubicin—thyroid cancer	0.000317	0.00143	CcSEcCtD
Prasugrel—Rash—Doxorubicin—thyroid cancer	0.000311	0.0014	CcSEcCtD
Prasugrel—Dermatitis—Doxorubicin—thyroid cancer	0.000311	0.0014	CcSEcCtD
Prasugrel—Headache—Doxorubicin—thyroid cancer	0.000309	0.0014	CcSEcCtD
Prasugrel—Nausea—Doxorubicin—thyroid cancer	0.000293	0.00132	CcSEcCtD
Prasugrel—CES2—E2F transcription factor network—CDK1—thyroid cancer	0.000292	0.0533	CbGpPWpGaD
Prasugrel—CYP2B6—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000227	0.0415	CbGpPWpGaD
Prasugrel—CES2—NRF2 pathway—SLC5A5—thyroid cancer	0.000185	0.0338	CbGpPWpGaD
Prasugrel—CES2—NRF2 pathway—RXRA—thyroid cancer	0.000156	0.0284	CbGpPWpGaD
Prasugrel—CES2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000151	0.0276	CbGpPWpGaD
Prasugrel—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.000144	0.0264	CbGpPWpGaD
Prasugrel—CES2—NRF2 pathway—NRG1—thyroid cancer	0.000135	0.0246	CbGpPWpGaD
Prasugrel—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000131	0.024	CbGpPWpGaD
Prasugrel—CYP2C19—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000131	0.024	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—CALCB—thyroid cancer	0.000128	0.0234	CbGpPWpGaD
Prasugrel—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00012	0.0219	CbGpPWpGaD
Prasugrel—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000103	0.0189	CbGpPWpGaD
Prasugrel—CYP2B6—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	8.96e-05	0.0164	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—CHST14—thyroid cancer	7.91e-05	0.0145	CbGpPWpGaD
Prasugrel—P2RY12—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	7.8e-05	0.0143	CbGpPWpGaD
Prasugrel—P2RY12—G alpha (i) signalling events—SST—thyroid cancer	7.62e-05	0.0139	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—CALCB—thyroid cancer	7.25e-05	0.0132	CbGpPWpGaD
Prasugrel—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	6.87e-05	0.0126	CbGpPWpGaD
Prasugrel—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	6.77e-05	0.0124	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—CALCB—thyroid cancer	6.58e-05	0.012	CbGpPWpGaD
Prasugrel—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	6.18e-05	0.0113	CbGpPWpGaD
Prasugrel—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	6.18e-05	0.0113	CbGpPWpGaD
Prasugrel—P2RY12—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	6.06e-05	0.0111	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	5.97e-05	0.0109	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—TSHR—thyroid cancer	5.94e-05	0.0109	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	5.45e-05	0.00996	CbGpPWpGaD
Prasugrel—CYP2B6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	5.42e-05	0.00991	CbGpPWpGaD
Prasugrel—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	5.39e-05	0.00986	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—PRKAR1A—thyroid cancer	5.22e-05	0.00955	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—PTCH1—thyroid cancer	5.05e-05	0.00923	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—SST—thyroid cancer	4.62e-05	0.00844	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—CALCA—thyroid cancer	4.44e-05	0.00812	CbGpPWpGaD
Prasugrel—CYP2B6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	4.39e-05	0.00803	CbGpPWpGaD
Prasugrel—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	4.1e-05	0.00749	CbGpPWpGaD
Prasugrel—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	4.07e-05	0.00745	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CALCB—thyroid cancer	3.89e-05	0.00711	CbGpPWpGaD
Prasugrel—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	3.73e-05	0.00683	CbGpPWpGaD
Prasugrel—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	3.71e-05	0.00679	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TRIM33—thyroid cancer	3.68e-05	0.00674	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	3.59e-05	0.00657	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—IFNA2—thyroid cancer	3.46e-05	0.00632	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—TSHR—thyroid cancer	3.35e-05	0.00613	CbGpPWpGaD
Prasugrel—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.32e-05	0.00607	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—TSHR—thyroid cancer	3.05e-05	0.00557	CbGpPWpGaD
Prasugrel—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.03e-05	0.00554	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PRKAR1A—thyroid cancer	3e-05	0.00548	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—SST—thyroid cancer	2.61e-05	0.00477	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—PTCH1—thyroid cancer	2.59e-05	0.00474	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—CALCA—thyroid cancer	2.51e-05	0.00459	CbGpPWpGaD
Prasugrel—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	2.46e-05	0.0045	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TCF7L1—thyroid cancer	2.46e-05	0.0045	CbGpPWpGaD
Prasugrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	2.45e-05	0.00448	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—SST—thyroid cancer	2.37e-05	0.00433	CbGpPWpGaD
Prasugrel—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	2.35e-05	0.0043	CbGpPWpGaD
Prasugrel—CYP2B6—Biological oxidations—RXRA—thyroid cancer	2.33e-05	0.00427	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—CALCA—thyroid cancer	2.28e-05	0.00417	CbGpPWpGaD
Prasugrel—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	2.24e-05	0.0041	CbGpPWpGaD
Prasugrel—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	2.24e-05	0.0041	CbGpPWpGaD
Prasugrel—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	2.15e-05	0.00392	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	2.09e-05	0.00382	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—CDK1—thyroid cancer	2.06e-05	0.00377	CbGpPWpGaD
Prasugrel—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	2e-05	0.00365	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	1.87e-05	0.00343	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TSHR—thyroid cancer	1.8e-05	0.00329	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PRKAR1A—thyroid cancer	1.77e-05	0.00324	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—RXRA—thyroid cancer	1.76e-05	0.00322	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—MINPP1—thyroid cancer	1.71e-05	0.00313	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	1.71e-05	0.00313	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MEN1—thyroid cancer	1.69e-05	0.00309	CbGpPWpGaD
Prasugrel—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	1.68e-05	0.00307	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	1.67e-05	0.00305	CbGpPWpGaD
Prasugrel—P2RY12—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.62e-05	0.00296	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—RXRA—thyroid cancer	1.61e-05	0.00294	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PTCH1—thyroid cancer	1.53e-05	0.0028	CbGpPWpGaD
Prasugrel—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	1.46e-05	0.00267	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NDUFA13—thyroid cancer	1.46e-05	0.00267	CbGpPWpGaD
Prasugrel—ALB—Metabolism—MINPP1—thyroid cancer	1.44e-05	0.00264	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—SST—thyroid cancer	1.4e-05	0.00256	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CHST14—thyroid cancer	1.37e-05	0.00251	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CALCA—thyroid cancer	1.35e-05	0.00246	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PRKAR1A—thyroid cancer	1.3e-05	0.00237	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—MINPP1—thyroid cancer	1.3e-05	0.00237	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—NRAS—thyroid cancer	1.29e-05	0.00236	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—TP53—thyroid cancer	1.25e-05	0.00228	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NDUFA13—thyroid cancer	1.23e-05	0.00224	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CDK1—thyroid cancer	1.22e-05	0.00223	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—MINPP1—thyroid cancer	1.18e-05	0.00216	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CHST14—thyroid cancer	1.15e-05	0.00211	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	1.14e-05	0.00209	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	1.14e-05	0.00209	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.12e-05	0.00205	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—KRAS—thyroid cancer	1.11e-05	0.00203	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—HPGD—thyroid cancer	1.1e-05	0.00202	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NDUFA13—thyroid cancer	1.1e-05	0.00201	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.06e-05	0.00194	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CHST14—thyroid cancer	1.04e-05	0.00189	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NDUFA13—thyroid cancer	1e-05	0.00184	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—TP53—thyroid cancer	9.87e-06	0.0018	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—NRG1—thyroid cancer	9.79e-06	0.00179	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CHST14—thyroid cancer	9.45e-06	0.00173	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—HRAS—thyroid cancer	9.44e-06	0.00173	CbGpPWpGaD
Prasugrel—ALB—Metabolism—HPGD—thyroid cancer	9.3e-06	0.0017	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TERT—thyroid cancer	8.79e-06	0.00161	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IFNA2—thyroid cancer	8.59e-06	0.00157	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	8.54e-06	0.00156	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—HIF1A—thyroid cancer	8.4e-06	0.00154	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—HPGD—thyroid cancer	8.35e-06	0.00153	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—AKT1—thyroid cancer	8.33e-06	0.00152	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—MINPP1—thyroid cancer	7.79e-06	0.00142	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—HPGD—thyroid cancer	7.61e-06	0.00139	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.54e-06	0.00138	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—NRAS—thyroid cancer	7.4e-06	0.00135	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.17e-06	0.00131	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—BRAF—thyroid cancer	6.96e-06	0.00127	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.77e-06	0.00124	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NDUFA13—thyroid cancer	6.63e-06	0.00121	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—KRAS—thyroid cancer	6.37e-06	0.00117	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—TPR—thyroid cancer	6.35e-06	0.00116	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	6.24e-06	0.00114	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CHST14—thyroid cancer	6.23e-06	0.00114	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.18e-06	0.00113	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—HRAS—thyroid cancer	5.42e-06	0.00099	CbGpPWpGaD
Prasugrel—ALB—Metabolism—TPR—thyroid cancer	5.34e-06	0.000977	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—AKT1—thyroid cancer	5.27e-06	0.000963	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PRKAR1A—thyroid cancer	5.26e-06	0.000961	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CCND1—thyroid cancer	5.08e-06	0.000929	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—HPGD—thyroid cancer	5.02e-06	0.000918	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PTEN—thyroid cancer	4.9e-06	0.000896	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—TPR—thyroid cancer	4.8e-06	0.000877	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—AKT1—thyroid cancer	4.78e-06	0.000874	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.76e-06	0.000871	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—SLC5A5—thyroid cancer	4.75e-06	0.000869	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	4.72e-06	0.000863	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—NRAS—thyroid cancer	4.37e-06	0.0008	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—TPR—thyroid cancer	4.37e-06	0.000799	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	4.3e-06	0.000787	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.28e-06	0.000782	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	4.01e-06	0.000734	CbGpPWpGaD
Prasugrel—ALB—Metabolism—SLC5A5—thyroid cancer	4e-06	0.000731	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—RXRA—thyroid cancer	3.99e-06	0.00073	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.9e-06	0.000713	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—KRAS—thyroid cancer	3.76e-06	0.000688	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.75e-06	0.000685	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SLC5A5—thyroid cancer	3.59e-06	0.000656	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.36e-06	0.000615	CbGpPWpGaD
Prasugrel—ALB—Metabolism—RXRA—thyroid cancer	3.36e-06	0.000614	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TP53—thyroid cancer	3.35e-06	0.000612	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SLC5A5—thyroid cancer	3.27e-06	0.000598	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.27e-06	0.000597	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—NRAS—thyroid cancer	3.2e-06	0.000586	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—HRAS—thyroid cancer	3.2e-06	0.000585	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.07e-06	0.000561	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—RXRA—thyroid cancer	3.02e-06	0.000551	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.93e-06	0.000536	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—TPR—thyroid cancer	2.88e-06	0.000527	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.84e-06	0.000519	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—AKT1—thyroid cancer	2.83e-06	0.000517	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—KRAS—thyroid cancer	2.76e-06	0.000504	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—RXRA—thyroid cancer	2.75e-06	0.000503	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.67e-06	0.000489	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PPARG—thyroid cancer	2.52e-06	0.000461	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—TP53—thyroid cancer	2.45e-06	0.000448	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—HRAS—thyroid cancer	2.34e-06	0.000428	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SLC5A5—thyroid cancer	2.16e-06	0.000395	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PPARG—thyroid cancer	2.12e-06	0.000388	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—AKT1—thyroid cancer	2.07e-06	0.000378	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTGS2—thyroid cancer	1.98e-06	0.000362	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PPARG—thyroid cancer	1.9e-06	0.000348	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—RXRA—thyroid cancer	1.81e-06	0.000332	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PPARG—thyroid cancer	1.74e-06	0.000317	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTEN—thyroid cancer	1.73e-06	0.000316	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTGS2—thyroid cancer	1.67e-06	0.000305	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTGS2—thyroid cancer	1.5e-06	0.000274	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTEN—thyroid cancer	1.46e-06	0.000266	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.37e-06	0.00025	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTEN—thyroid cancer	1.31e-06	0.000239	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTEN—thyroid cancer	1.19e-06	0.000218	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PPARG—thyroid cancer	1.15e-06	0.000209	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—AKT1—thyroid cancer	9.96e-07	0.000182	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTGS2—thyroid cancer	9.01e-07	0.000165	CbGpPWpGaD
Prasugrel—ALB—Metabolism—AKT1—thyroid cancer	8.39e-07	0.000153	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTEN—thyroid cancer	7.86e-07	0.000144	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—AKT1—thyroid cancer	7.53e-07	0.000138	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—AKT1—thyroid cancer	6.87e-07	0.000126	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—AKT1—thyroid cancer	4.53e-07	8.28e-05	CbGpPWpGaD
